Regado Biosciences has landed $23 million in Series C financing. New investor Caxton Advantage Life Sciences Fund, Domain Associates and Quaker BioVentures led the round. The company will use the funding to advance its lead drug, REG1. "We are excited about the prospects for Regado...REG1 has the potential to address some key issues with today's anticoagulants used in antithrombotic markets such as CABG, PCI, and ACS," said Eric Roberts, Managing Director of Caxton Advantage.
- read the company's release for more